• BOP Reagent: Evidence, Scope, and Prodrug Chemistry

  2026-10-08

  BOP reagent supports conceptually important carboxyl group activation, amide bond formation, and phenyl ester preparation. This evidence-focused analysis separates the reagent’s documented chemical role from the biological claims of a carrier-free triterpene prodrug study.

• 6-OHDA Hydrochloride and Neuronal DNA Repair

  2026-10-08

  6-OHDA hydrochloride provides a useful conceptual lens for studying how neuronal stress may influence genome-editing outcomes. This article connects neurotoxicity modeling with findings from a 2025 study of CRISPR repair in nondividing human neurons while clearly separating reported evidence from interpretation.

• CAPE and NF-κB in Neurodegeneration Research

  2026-10-07

  Caffeic Acid Phenethyl Ester (CAPE) is commonly discussed as an NF-κB pathway probe, while a 2024 zebrafish study identified coordinated Stat3 and NF-κB signaling in Fyn-driven dopaminergic neurodegeneration. The findings support a research rationale for studying CAPE in this context, but they do not show that CAPE was tested in the published model or establish therapeutic relevance.

• Gly-Gly-Phe-Gly (GGFG): Evidence and Uses

  2026-10-07

  Gly-Gly-Phe-Gly, also called the GGFG peptide, is a four-residue research material described as a flexible peptide linker or spacer. The available product record supports its use in conceptual drug conjugation research, but the supplied peer-reviewed study concerns KR-12–Cu(II) binding rather than GGFG, so it does not establish GGFG efficacy or mechanism.

• Triterpene Prodrug for Targeted Oral Cancer Therapy

  2026-10-06

  The 2024 ACS Applied Materials & Interfaces study describes a carrier-free, self-assembled prodrug built from glycyrrhetinic acid and ginsenoside Rh2 for oral squamous cell carcinoma. Its central concept combines ROS-responsive release, glucose-related tumor-cell uptake, and glycyrrhetinic-acid-driven oxidative amplification, although the findings remain preclinical and require independent validation.

• Ziprasidone HCl and GOT1 in Pancreatic Cancer

  2026-10-06

  A source-grounded overview of ziprasidone hydrochloride as a preclinical GOT1 inhibitor in pancreatic ductal adenocarcinoma, covering metabolic rationale, published findings, evidence strength, conceptual applications, and translational limitations.

• Imidazoline Antagonists and β-Cell K+ Channels

  2026-10-05

  Jonas, Plant, and Henquin showed that several imidazoline α2-adrenoceptor antagonists enhance insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, rather than through α2-adrenoceptor blockade alone. By combining insulin secretion, 86Rb efflux, and patch-clamp evidence, the study established a channel-level explanation for a pharmacological effect previously attributed mainly to adrenergic antagonism.

• Fingolimod (FTY720): Evidence, Uses, and Limits

  2026-10-05

  Fingolimod is an S1P receptor modulator with established clinical value in multiple sclerosis through lymphocyte egress inhibition. This overview separates evidence from interpretation, compares clinical, mechanistic, preclinical, and supplier-level claims, and explains why a 2026 magnetic CAR-T-mimicking-cell study does not establish a role for Fingolimod in that platform.

• Hexose Diphosphate: Evidence and Research Context

  2026-10-04

  Hexose diphosphate is a carbohydrate-phosphate research material relevant to metabolic studies, but the supplied evidence does not establish it as the phosphoenolpyruvate described in a 2026 Nature Aging study. This overview separates catalog information from published findings, evaluates possible research applications, and defines the limitations of extending PEP-related results to hexose phosphate biology, inflammation, ischemia, or aging.

• Cyclo (-RGDfC): From Integrin Binding to Translation

  2026-10-03

  Cyclo (-RGDfC) is best understood not simply as an RGD reagent, but as a mechanistic probe for testing how αvβ3 integrin biology translates into spatially controlled, reproducible cancer and angiogenesis research. This article separates catalog specifications from published evidence and outlines a translational framework without overstating clinical readiness.

• Temafloxacin Assays: Applied Workflow and Troubleshooting

  2026-10-02

  Temafloxacin supports reproducible MIC, intracellular killing, atypical-pathogen, and respiratory infection workflows when concentration, inoculum, and endpoint are aligned. This guide translates comparative spectrum and tissue-penetration evidence into practical assay design, optimization, and troubleshooting decisions.

• Laminin (925-933) Protocol for Adhesion & Chemotaxis

  2026-10-01

  Laminin (925-933) is a defined Laminin B1 chain peptide for testing cell attachment, receptor-associated migration, and chemotactic responses without using full-length laminin. This guide provides setup and QC recommendations for research assays, but the peptide should not be treated as a complete basement membrane substitute or used for diagnostic or medical purposes.

• HOBt (1-Hydroxybenzotriazole) Workflow

  2026-10-01

  HOBt supports high-fidelity amide bond formation when stereochemical control and difficult carboxylic acids matter. This practical guide connects peptide synthesis, medicinal-chemistry coupling, and troubleshooting to the indazole-based glucagon receptor antagonist study.

• Panobinostat Targets MLL-Rearranged ALL In Vivo

  2026-09-30

  This study shows that the HDAC inhibitor panobinostat produces meaningful anti-leukaemic activity in xenograft models of MLL-rearranged acute lymphoblastic leukaemia. Its mechanistic contribution is the identification of suppressed RNF20/RNF40/WAC-dependent histone H2B ubiquitination as a molecular event connecting epigenetic treatment to leukaemic cell death.

• Mitochondrial Calcium Signaling and Ferroptosis

  2026-09-30

  The reference study identifies mitochondrial calcium uniporter (MCU) activity as a regulator of GPX4 function through acetyl-CoA-dependent modification of GPX4 at lysine 90. Genetic, biochemical, structural, and tumor-model evidence connects mitochondrial calcium signaling with ferroptosis suppression and provides a framework for interpreting ferroptosis assay results.

7919 records 1/528 page Next 12345 下5页 Last page